Semaglutide Benefits Obesity-Related Heart Failure Equally in Patients With and Without Atrial Fibrillation
In the STEP-HFpEF program (1,145 patients), semaglutide improved heart failure symptoms, weight, CRP, and NT-proBNP regardless of atrial fibrillation status — with even greater symptom improvements in those who had AF.
Quick Facts
What This Study Found
Semaglutide 2.4 mg improved HFpEF outcomes regardless of AF status, with greater symptom improvements in AF patients (KCCQ-CSS +11.5 vs +4.3 points; P interaction=0.001).
Key Numbers
Semaglutide 2.4 mg once weekly; STEP-HFpEF and STEP-HFpEF DM trials pooled; stratified by AF status.
How They Did This
Pre-specified secondary analysis of pooled data from STEP-HFpEF and STEP-HFpEF DM randomized trials. 1,145 patients with HFpEF and BMI ≥30, randomized 1:1 to semaglutide 2.4 mg vs placebo for 52 weeks, stratified by AF history.
Why This Research Matters
AF and HFpEF often coexist, and clinicians need to know if treatments work across both conditions. This analysis confirms semaglutide benefits are not diminished by AF — and may actually be amplified in this higher-risk subgroup.
The Bigger Picture
This analysis addresses a critical clinical question: should AF patients with obesity-related HFpEF receive semaglutide? The answer is a clear yes — and these patients may actually derive the most benefit, potentially changing how cardiologists approach this common comorbidity combination.
What This Study Doesn't Tell Us
Secondary/subgroup analysis — not powered for the AF subgroup comparison as a primary endpoint. AF history was investigator-reported, not adjudicated. AF types (paroxysmal, persistent, permanent) had varying sample sizes. 52-week follow-up may not capture long-term outcomes.
Questions This Raises
- ?Does semaglutide reduce new-onset AF in obesity-related HFpEF patients?
- ?Why does AF amplify semaglutide's symptom benefits — is it the weight loss, inflammation reduction, or hemodynamic effects?
- ?Should semaglutide be considered as part of AF management in obese HFpEF patients?
Trust & Context
- Key Stat:
- +11.5 vs +4.3 point KCCQ improvement Semaglutide produced greater HF symptom improvements in patients with AF vs without AF
- Evidence Grade:
- Strong evidence — secondary analysis of two well-designed, large randomized trials. Consistent results across endpoints increase confidence despite subgroup design.
- Study Age:
- Published in 2024. Part of the landmark STEP-HFpEF program establishing semaglutide's role in obesity-related heart failure.
- Original Title:
- Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.
- Published In:
- Journal of the American College of Cardiology, 84(17), 1603-1614 (2024)
- Authors:
- Verma, Subodh(15), Butler, Javed(16), Borlaug, Barry A(17), Davies, Melanie J, Kitzman, Dalane W, Petrie, Mark C, Shah, Sanjiv J, Jensen, Thomas Jon, Rasmussen, Søren, Rönnbäck, Cecilia, Merkely, Bela, O'Keefe, Evan, Kosiborod, Mikhail N
- Database ID:
- RPEP-09437
Evidence Hierarchy
Frequently Asked Questions
Can I take semaglutide if I have both heart failure and an irregular heartbeat?
Yes — this analysis of over 1,100 patients showed that semaglutide worked well regardless of whether patients had atrial fibrillation. In fact, patients with AF who took semaglutide had even greater improvements in heart failure symptoms than those without AF.
Why might semaglutide help more in patients with atrial fibrillation?
Patients with AF tend to have more advanced heart failure, more inflammation, and higher BMI. Semaglutide's multi-pronged benefits — weight loss, inflammation reduction, and improved cardiac function — may provide more room for improvement in these sicker patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09437APA
Verma, Subodh; Butler, Javed; Borlaug, Barry A; Davies, Melanie J; Kitzman, Dalane W; Petrie, Mark C; Shah, Sanjiv J; Jensen, Thomas Jon; Rasmussen, Søren; Rönnbäck, Cecilia; Merkely, Bela; O'Keefe, Evan; Kosiborod, Mikhail N. (2024). Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.. Journal of the American College of Cardiology, 84(17), 1603-1614. https://doi.org/10.1016/j.jacc.2024.08.023
MLA
Verma, Subodh, et al. "Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.." Journal of the American College of Cardiology, 2024. https://doi.org/10.1016/j.jacc.2024.08.023
RethinkPeptides
RethinkPeptides Research Database. "Atrial Fibrillation and Semaglutide Effects in Obesity-Relat..." RPEP-09437. Retrieved from https://rethinkpeptides.com/research/verma-2024-atrial-fibrillation-and-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.